| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| catumaxomab | t-cell surface glycoprotein cd3 epsilon chain | biotech | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Malignant Neoplasms[MeSHID:D009369] Ascites[MeSHID:D001201] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of ovary[MeSHID:D010051] Pleural Effusion Malignant[MeSHID:D016066] |
4.77 | approved,investigational,withdrawn | agonist,antibody |
| catumaxomab | t-cell surface glycoprotein cd3 epsilon chain | biotech | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Malignant Neoplasms[MeSHID:D009369] Ascites[MeSHID:D001201] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of ovary[MeSHID:D010051] Pleural Effusion Malignant[MeSHID:D016066] |
4.77 | approved,investigational,withdrawn | agonist |
| catumaxomab | epithelial cell adhesion molecule | biotech | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Malignant Neoplasms[MeSHID:D009369] Ascites[MeSHID:D001201] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of ovary[MeSHID:D010051] Pleural Effusion Malignant[MeSHID:D016066] |
5.97 | approved,investigational,withdrawn | ligand,antibody |
| catumaxomab | epithelial cell adhesion molecule | biotech | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Malignant Neoplasms[MeSHID:D009369] Ascites[MeSHID:D001201] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of ovary[MeSHID:D010051] Pleural Effusion Malignant[MeSHID:D016066] |
5.97 | approved,investigational,withdrawn | ligand |
| catumaxomab | high affinity immunoglobulin gamma fc receptor i | biotech | NA | drugbank | Disease Management[MeSHID:D019468] Malignant Neoplasms[MeSHID:D009369] Ascites[MeSHID:D001201] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of ovary[MeSHID:D010051] Pleural Effusion Malignant[MeSHID:D016066] |
NA | approved,investigational,withdrawn | agonist |
| catumaxomab | low affinity immunoglobulin gamma fc region receptor ii-a | biotech | NA | drugbank | Disease Management[MeSHID:D019468] Malignant Neoplasms[MeSHID:D009369] Ascites[MeSHID:D001201] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of ovary[MeSHID:D010051] Pleural Effusion Malignant[MeSHID:D016066] |
NA | approved,investigational,withdrawn | agonist |
| catumaxomab | low affinity immunoglobulin gamma fc region receptor iii-a | biotech | NA | drugbank | Disease Management[MeSHID:D019468] Malignant Neoplasms[MeSHID:D009369] Ascites[MeSHID:D001201] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of ovary[MeSHID:D010051] Pleural Effusion Malignant[MeSHID:D016066] |
NA | approved,investigational,withdrawn | agonist |
| catumaxomab | low affinity immunoglobulin gamma fc region receptor iii-b | biotech | NA | drugbank | Disease Management[MeSHID:D019468] Malignant Neoplasms[MeSHID:D009369] Ascites[MeSHID:D001201] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of ovary[MeSHID:D010051] Pleural Effusion Malignant[MeSHID:D016066] |
NA | approved,investigational,withdrawn | agonist |
| click here to return to the previous page | ||||||||